Winship Cancer Institute of Emory University | Strategic Alliance Partners

Suresh S. Ramalingam, MD, FACP, FASCO, discusses current applications for frontline immunotherapy and targeted therapy for non–small cell lung cancer and the current management of small cell lung cancer.

Since most diagnoses of esophageal squamous cell carcinoma are made when the disease is in advanced stages, investigators have initiated studies to evaluate the efficacy of immunotherapy in earlier lines of therapy, including in combination with chemoradiotherapy.

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.

Ticiana Leal, MD, discusses the utilization of PD-1 and PD-L1 inhibitor monotherapy in lung cancer.

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the results of an exploratory analysis of the ongoing phase 3 CheckMate 227 trial in advanced non–small cell lung cancer.

The dual immunotherapy combination comprised of nivolumab and ipilimumab improved overall survival vs chemotherapy in patients with advanced non–small cell lung cancer, irrespective of KRAS, TP53, or STK11 mutational status, according to data from exploratory analyses of part 1 of the CheckMate-227 trial.

Sagar Lonial, MD, FACP, discusses the management of belantamab mafodotin-blmf–related keratopathy in patients with relapsed/refractory multiple myeloma.

Ticiana Leal, MD, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer.

Bassel El-Rayes, MD, discusses the efficacy of tidutamab in advanced neuroendocrine tumors.

Iberdomide combined with dexamethasone and either daratumumab, bortezomib, or carfilzomib showed efficacy and tolerability in patients with relapsed or refractory multiple myeloma.

The addition of veliparib to platinum-based chemotherapy in the frontline treatment of current smokers with advanced squamous non–small cell lung cancer did not significantly improve overall survival, but the LP52 signature may identify a subset of patients who will derive benefit from the combination.

Suresh S. Ramalingam, MD, has been named executive director of Winship Cancer Institute of Emory University.

Suresh S. Ramalingam, MD, FASCO, discusses updated data with mobocertinib in EGFR exon 20 insertion–positive advanced non–small cell lung cancer.

The use of 18F-fluciclovine-PET/CT in guiding salvage treatment with radiotherapy after prostatectomy reduced the likelihood of biochemical recurrence or suboptimal response to treatment in patients with prostate cancer without evidence of extrapelvic disease with conventional imaging.

Dr. Saba shares the ins and outs of nasopharyngeal carcinoma, ongoing clinical trials, and the complexities of managing the rare disease.

Jane L. Meisel, MD, discusses the potential utility of CDK4/6 inhibitors in HER2-positive metastatic breast cancer.

Manali Bhave, MD, discusses promising combination strategies in triple-negative breast cancer.

Nabil F. Saba, MD, FACP, discusses some of the unique characteristics of nasopharyngeal carcinoma.

Jane L. Meisel, MD, discusses sequencing questions, tucatinib combinations under exploration, and emerging strategies for use in the treatment of patients with HER2-positive breast cancer.

Jane L. Meisel, MD, discusses managing toxicities associated with ado-trastuzumab emtansine in patients with HER2-positive breast cancer.

Jane L. Meisel, MD, discusses some of the nuances of utilizing adjuvant ado-trastuzumab emtansine in HER2-positive breast cancer.

Kevin Kalinsky, MD, MS, discusses the potential role of ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Suresh S. Ramalingam, MD, FASCO, deputy director, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treatment after osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

The 3 most common types of amyloidosis––TTR mutant, TTR wild-type, and amyloid light chain––have a significant amount of cardiac involvement, making cardiologists essential players in the diagnostic workup and treatment of these patients

The FDA's accelerated approval of sacituzumab govitecan-hziy in April 2020, filled a previously undefined role for antibody-drug conjugates in patients with triple-negative breast cancer.

With the identification of numerous molecular abnormalities that can affect treatment and the course of disease in patients with breast cancer, it’s become understood that genetic profiling can define clinical trial eligibility, the presence or absence of aberrations help to drive treatment decisions, and variants can be predictive for response or resistance.

Ajay K. Nooka, MD, MPH, FACP, discusses the utility of BCMA as a target in multiple myeloma.

Jane L. Meisel, MD, discusses sequencing considerations in the first- and second-line settings of HER2-positive breast cancer.

Ragini Kudchadkar, MD, discusses future research directions for patients with rare, non-melanoma skin cancers.

Nabil F. Saba, MD, FACP, discusses the results of the JAVELIN Head and Neck 100 trial, as well as data from other key, recent studies in head and neck cancer.